摘要
Abstract
OBJECTIVE:To probe into the clinical efficacy of montelukast sodium combined with salmeterol and fluticasone in treatment of chronic obstructive pulmonary disease ( COPD ) .METHODS: 124 patients with COPD admitted into Henan Tanghe County Traditional Chinese Medicine Hospital from Jun .2015 to May 2016 were extracted to be divided into observation group and control group via the random number table , with 62 cases in each .The control group was given salmeterol and fluticasone propinate for inhalation , while the observation group additionally received montelukast sodium tablets based on the control group;the treatment course was 12 weeks .The clinical efficacy , lung function indices , dyspnea score , daily life ability score , number of admissions and incidence of adverse drug reactions within one year of follow-up of two groups were observed .RESULTS:The total effective rate of observation group was 96.77％(60/62), significantly higher than that of control group [80.65％(50/62)].After treatment, the FVC and FEV1 of observation group were better than those of control group , the dyspnea score was significantly lower than the control group , and the daily life ability score was higher than that of control group , with statistically significant differences(P<0.05).After follow-up of 1 year, the average number of admissions of observation group was (0.4 ± 0.2) times, significantly lower than that of control group (1.1 ±0.1) times, with statistically significant difference (P<0.05).The incidence of adverse drug reactions of two groups were respectively 3.23％(2/62) and 4.84％(3/62), without any statistically significant differences ( P>0.05).CONCLUSIONS: The efficacy of montelukast sodium combined with salmeterol and fluticasone in treatment of COPD is remarkable , which can improve patients ' lung function and life quality with few adverse drug reactions .关键词
慢性阻塞性肺疾病/孟鲁司特钠/沙美特罗替卡松/疗效/肺功能Key words
COPD/Montelukast sodium/Salmeterol and fluticasone/Clinical efficacy/Lung function分类
医药卫生
